The American Academy of Neurology (AAN) held its Annual Meeting from April 22-28, 2022. During the meeting, various stakeholders discussed trends, science, and research within the field of neurology. According…
During the Phase 1/2 SUNRISE clinical trial, which evaluated LB-001 for pediatric patients with methylmalonic acidemia, at least two participants experienced serious and severe adverse reactions: thrombotic microangiopathy. While investigating…
Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…
Clinical trials are an important tool within the healthcare realm. These trials assist in developing deeper understandings of diseases, assessing and discovering treatment options, and learning new ways of identification…
A new treatment for Rett syndrome is officially being studied in humans in Canada, meaning Canadian patients may have a new, viable treatment option in the future. Called TSHA-102, this…
Clinical trials are important in developing a better understanding of certain diseases or conditions, as well as how to treat them. According to HCP Live, researchers evaluated PRX-102 (pegunigalsidase alfa),…
According to a recent press release, the Australian Human Research Ethics Committee (HREC) has granted approval to Claritas Pharmaceuticals' submission for R-107. Now, the company is free to move forward with…
According to a recent article in Businesswire, The Lancet has published data from the third phase of the Marigold trial. This clinical trial evaluated ganaxalone - marketed as ZTALMY - as a…
According to a recent press release from Respira Therapeutics, their investigational treatment for pulmonary arterial hypertension (PAH), RT234, has just been administered to the first patient in a phase 2b…
Two years ago, China approved ensartinib as a second-line therapy for those with ALK+ non-small cell lung cancer (NSCLC). There have been advances over time. Now, according to a late…
In a Phase 3 clinical trial, researchers evaluated I/ONTAK (also known as E7777) as a potential therapeutic option for persistent or recurrent cutaneous T-cell lymphoma (CTCL). According to Targeted Oncology,…
In a late March 2022 news release from biopharmaceutical company CANbridge Pharmaceuticals, Inc. ("CANbridge"), the company noted that the first patient was dosed in a Phase 1b/2 clinical trial evaluating…
Earlier this year, 4D Pharma Plc. ("4D Pharma") experienced a "win" when the FDA approved the company's plans to initiate a Phase 1 clinical trial evaluating MRx0005 and MRx0029 for Parkinson's…
On March 29, 2022, globally diversified chemical company LG Chem announced via press release that its Investigational New Drug (IND) application was approved by the U.S. Food and Drug Administration…
Currently, there are no cures for idiopathic pulmonary fibrosis (IPF), and the two available treatments aim to reduce lung scarring and symptom progression. However, it is clear that new therapeutic…
Without treatment, an estimated 20% of those with progressive keratoconus may eventually require corneal transplantation. Glaukos, a company creating novel therapies for chronic eye diseases, developed the iLink corneal cross-linking procedure to…
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting took place this year from February 25-28, 2022. During the meeting, stakeholders gathered to discuss new technologies, healthcare reform,…
According to a story from Targeted Oncology, the company Genmab has recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to its investigational therapy…
ProQR Therapeutics is working to develop unique therapeutic solutions for genetic eye diseases. Currently, the company is evaluating its therapeutic candidate ultevursen within the Phase 2/3 Sirius and Celeste clinical trials; you can read…
Each year, an estimated 11,000 people across the globe are diagnosed with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL). However, there is only one…
Over the last few years, there has been much discussion around VLA1553, a Chikungunya virus vaccine candidate. The vaccine has so far earned Fast Track and Breakthrough Therapy designations within…
Clinical trials are greatly beneficial in understanding more about therapeutics and various conditions. For example, the Phase 3 VIITAL trial will evaluate the safety, efficacy, and tolerability of EB-101, an…
The first patient has been dosed in the Phase 1/2 B-LIEVE trial of FLT180a, an investigational treatment for hemophilia B. Freeline Therapeutics, the drug developer, announced the news in a…
In late February 2022, biopharmaceutical company Trascenta Holding Limited ("Trascenta") provided an update on its clinical program for TST001, a monoclonal antibody therapy designed for those with locally advanced or…
Cancer Network recently featured a press release by CTI BioParma announcing that the FDA has given accelerated approval for pacritinib to treat patients diagnosed with myelofibrosis and severely low platelets…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
